Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Linoleyl carbonate-paclitaxel conjugate - American Regent

Next Previous
Drug Profile

Linoleyl carbonate-paclitaxel conjugate - American Regent

Alternative Names: 2-linoleyl carbonate-paclitaxel; LOC-pac; LOC-paclitaxel

Latest Information Update: 15 Jan 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Luitpold Pharmaceuticals
  • Developer Luitpold Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Class Albumins; Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
  • Mechanism of Action Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Malignant melanoma

Most Recent Events

  • 02 Jan 2019 Luitpold Pharmaceuticals is now called American Regent
  • 28 Dec 2017 No recent reports of development identified for phase-I development in Malignant-melanoma(Metastatic disease) in USA (IV, Infusion)
  • 01 Feb 2016 Luitpold Pharmaceuticals terminates a phase I trial in Malignant melanoma (Metastatic disease, Second-line therapy or greater) in USA due to early positive results (NCT01039844)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top